Cixutumumab

Research use only, not for human use.

Cixutumumab (IMC-A12), a humanized monoclonal antibody targeting IGF-1R, exhibits high affinity and inhibits ligand-dependent receptor activation, impeding downstream signaling.

Cixutumumab (IMC-A12) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.

Cixutumumab (IMC-A12) (0.01-100 nM; 96 h) exhibits at least 50% growth inhibition in CHLA-9, TC-71and Rh41 cells.Cell Viability Assay Cell Line:CHLA-9, TC-71, Rh41 cells Concentration:0.01-100 nM Incubation Time:96 h Result:Inhibited CHLA-9, TC-71and Rh41 cells growth with IC50 values of 49.31, 0.66 and 0.04 nM, respectively.

Cixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels.Animal Model:CB17SC-M scid-/- female mice (solid tumor xenografts model).Dosage:1 mg/rat Administration:Intraperitoneal injection; twice weekly for 6 weeks.Result:Demonstrated broad antitumor activity against the PPTP’s in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression.

——

Others

Other Targets

Others

——

——

947687-12-9

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years